Effectiveness of Pfizer’s RSV vaccine could reduce disease burden in older adults

The bivalent respiratory syncytial virus prefusion F, or RSVpreF, vaccine may prevent one hospitalization or ED visit tied to the infection for every 250 vaccinated older adults, an analysis showed.
The data are consistent with recent findings on respiratory syncytial virus (RSV) vaccine effectiveness and suggest the opportunity “to reduce severe medically attended RSV disease burden,” the researchers wrote in JAMA Network Open.
The CDC’s Advisory Committee on Immunization Practices (ACIP) said in June 2023 that adults 60 years of age or older may receive one of the two RSV

The bivalent respiratory syncytial virus prefusion F, or RSVpreF, vaccine may prevent one hospitalization or ED visit tied to the infection for every 250 vaccinated older adults, an analysis showed.
The data are consistent with recent findings on respiratory syncytial virus (RSV) vaccine effectiveness and suggest the opportunity “to reduce severe medically attended RSV disease burden,” the researchers wrote in JAMA Network Open.
The CDC’s Advisory Committee on Immunization Practices (ACIP) said in June 2023 that adults 60 years of age or older may receive one of the two RSV